Full Picture

Article analysis:

The article is generally reliable and trustworthy, as it provides detailed information on the research conducted and its results. The authors have used a variety of data sources from TCGA-BRCA, METABRIC, GSE21653, GSE176078, GSE75688, GSE<> and KM Plotter databases to validate their model. Furthermore, they have created a user-friendly website to promote the application of their CDI prediction model in post-surgery TNBC.

However, there are some potential biases that should be noted when assessing the trustworthiness and reliability of this article. Firstly, the authors have only explored one side of the argument – that PCD can be used as an indicator for predicting post-surgery prognosis and drug sensitivity in TNBC patients – without considering any counterarguments or alternative approaches that could be taken. Additionally, while the authors provide evidence for their claims by citing relevant studies and data sources, they do not provide any evidence for their claim that high CDI TNBC patients are resistant to standard adjuvant chemotherapy but may be sensitive to palbociclib. Furthermore, there is no discussion on possible risks associated with using PCD as an indicator for predicting post-surgery prognosis and drug sensitivity in TNBC patients.

In conclusion, while this article is generally reliable and trustworthy due to its detailed information on research conducted and results obtained from various data sources, there are some potential biases that should be noted when assessing its trustworthiness and reliability such as lack of consideration for counterarguments or alternative approaches; lack of evidence for certain claims; lack of discussion on possible risks associated with using PCD as an indicator; etc.